News & Press

2024 Robert F. Gagel ITOG Discovery Award Winner: Jim Fagin, MD

Wed, 22 Jan 2025 17:37:00 GMT

2024 Robert F. Gagel ITOG Discovery Award Winner: Jim Fagin, MD for “Leveraging therapeutic vulnerabilities induced by cGAS-STING activation in ATC”

Congratulations to Dr. Fagin and thank you to all who sent in proposals for consideration. Your efforts and contributions are essential to ITOG’s important Mission of “Catalyzing a Cure for Thyroid Cancer”!

2023 Winter Annual Newsletter

Fri, 16 Feb 2024 19:11:00 GMT

2023 Annual Newsletter Click here to view

ACCRU-ITOG-1504 Achieves Accrual Goal

Fri, 15 May 2020 20:16:56 GMT

Congratulations to Principal Investigator: Bryan Haugen at The University of Colorado Cancer Center and his team for achieving accrual goal of 60 ACCRU-ITOG-1504: Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study.

ITOG Robert F. Gagel Discovery Award Recipient Carmelo Nucera, MD

Mon, 6 Apr 2020 20:54:21 GMT

Please join us in congratulating the 2019 Robert F. Gagel ITOG Discovery Award Recipient, Carmelo Nucera, MD for his submission “Engineering a new mouse model of a thyroid-specific lincRNA in BRAFV600E papillary thyroid carcinoma.”

LOXO-292 demonstrates promising anti-tumor activity in RET-altered thyroid cancer

Mon, 6 Apr 2020 20:42:19 GMT

ITOG member Dr. Lori Wirth recently presented progress on a Phase 1/2 study of LOXO-292 at the European Society for Medical Oncology (ESMO) Annual Congress in Barcelona, Spain. This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LOXO-292 administered orally to patients with advanced solid tumors, including RET-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

Read More

ITOG Selumetinib Trial Achieves Accrual Goal!

Mon, 6 Apr 2020 20:36:31 GMT

ITOG Selumetinib Trial Achieves Accrual Goal!

Congratulations to Principal Investigator: Alan Ho, MD at Memorial Sloan-Kettering Cancer Center and his team for achieving accrual goal of 60 for the Selumetnib plus RAI for RAI-Avid Thyroid Cancer.

ITOG Board of Directors Announces a New International Board Member

Fri, 11 Oct 2019 17:33:42 GMT

ITOG is pleased to announce that Dr. Sophie Leboulleux has been elected as the newest international member of the ITOG Board of Directors. Sophie Leboulleux is board certified in endocrinology, nuclear medicine and oncology. She works in the Department of Nuclear Medicine and Endocrine Oncology in Villejuif, France where she is responsible for the Thyroid Cancer Multidisciplinary Team. Her current clinical interests include treatment and follow up of thyroid cancer from thyroid nodule to radioactive iodine refractory thyroid cancer and imaging of cancer with TEP. Her current research is focused on the role of adjuvant radioactive treatment administration and on radioactive refractory thyroid cancer. She leads a prospective randomized study on the utility of postoperative radioactive iodine treatment, a prospective study on redifferentiation and has been co-investigator for trials in radioactive iodine refractory differentiated thyroid cancer and medullary thyroid cancer. She is Associate Professor, Chief of the Department of Nuclear Medicine in Villejuif and Associate Professor in the Department of Endocrine Oncology. ITOG is fortunate to have such qualified individuals to serve on the board of directors, ensuring commitment to the mission of ITOG in catalyzing effective treatments for thyroid cancer. The Board of Directors would like to extend its thanks to Cosimo Durante, MD, PhD University of Rome, Sapienza, Rome, Italy and Christine Spitzweg, MD, University Hospital Munich, Ludwig-Maximilians-University, Munich for standing for election, their level of commitment to ITOG is remarkable and is a source of inspiration for all.